Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes: Are we all becoming "Interventional" Cardiologists?

Journal of the American College of Cardiology

Volumn 40, Issue 11, 2002, Pages 1915-1918

  Yarlagadda, Ravi K ^a,b   Boden, William E ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DALTEPARIN; DOBUTAMINE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROTECTIVE AGENT; THROMBIN INHIBITOR; TIROFIBAN; VASODILATOR AGENT;

ANGIOCARDIOGRAPHY; CLINICAL TRIAL; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART SCINTISCANNING; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; STRESS ECHOCARDIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0037021518     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02571-8     Document Type: Editorial

References (31)

1. American Heart Association. Heart and Stroke Facts: 2002 Statistical Update. Dallas, TX: American Heart Association, 2001.
2. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89:1545-56.
3. Anderson HV, Canon CP, Stone PH, et al. One year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
4. Boden WE, O'Rourke RA, Crawford MH, et al., The Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-92.
5. FRagmin and Fast Revascularization during InStabilty in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-15.
6. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomized trial. Lancet 2000;356:9-16.
7. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
8. Braunwald E, Antman EM, Beasley JW, et al. Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. Available at: http:/www.acc.org/clinica/guidelines/unstable/update_index.htm.
9. Lagerqvist B, Husted S, Kontny F, et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: A two-year follow-up of the FRISC II invasive study. J Am Coll Cardiol 2002;40:1902-14.
10. Barnett PG, Chen S, Boden WE, et al. Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction: Results of a randomized trial. Circulation 2002;105:680-4.
11. Lagerqvist B, Safastrom K, Stahle E, et al., FRISC II Study Group Investigators. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? J Am Coll Cardiol 2001;38:41-8.
12. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events. J Am Coll Cardiol 2000;36:693-8.
13. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-601.
14. Lincoff AM, Califf RM, Anderson KM, et al., for the EPIC Investigators. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by Abciximab (abciximab Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:149-56.
15. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-35.
16. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
17. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
18. The IMPACT II Investigators. Randomised placebo-controlled trial of the effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-8.
19. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445-53.
20. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a Global Organization Network. Circulation 1998;97:2386-95.
21. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy. N Engl J Med 1998;339:436.
22. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM). N Engl J Med 1998;338:1498-505.
23. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS). N Engl J Med 1998;338:1488-97.
24. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
25. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. JAMA 2001;285:1711-8.
26. Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215-22.
27. The Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
28. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
29. Robbins M, Topol EJ. Inflammation in acute coronary syndromes. Cleveland Clin J Med 2002;69 Suppl 2:SII130-42.
30. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-26.
31. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.